Logo
Call us: 91-11-42141242
Email: info@marketsmonitor.com
HOME COMPANY SECTORS CONTACTS
  • USING ANALYTICS

    TO ACHIEVE HIGH PERFORMANCE
 

Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018


Published: Dec, 2011
Pages: 79
Format:Adobe Reader (PDF) Upto 24 hour delivery
Pub ID: MM1325847270
Pricing:
  Regular Discounted
Local PDF $ 3,500.00 $ 2,800.00
Global PDF $ 10,500.00 $ 8,400.00


GlobalData, the industry analysis specialist, has released its new report, “Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Crohn’s Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Crohn’s Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated that the global Crohn’s disease (CD) therapeutics market was worth $3.6 billion in 2010 which grew at a compound annual growth rate (CAGR) of 25.2%, from $1.2 billion in 2005. This high growth rate during the period 2005-2010 was primarily attributed to the launch of the biologics such as Humira (adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab) and the increased uptake of the biologics Remicade (infliximab) and Entocort EC (budesonide). The CD therapeutics market is forecast to show moderate growth at a CAGR of 2.6% for the next eight years, to reach $4.4 billion by 2018. This reduced growth will come as a result of the patent expiries of Remicade and Entocort EC and the subsequent launch of biosimilars in the forecast period. The CD therapeutics pipeline is strong, with first-in-class molecules in the late stage of development, which when launched are expected to off-set the generic incursion and drive the market.

Scope

The report provides information on the key drivers and challenges for the CD therapeutics market. Its scope includes -
- Annualized information for the CD therapeutics market in the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) with revenue data from 2005–2010 and forecasts to 2018.
- Pipeline analysis data which provides information on different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as interleukin inhibitors and enzyme inhibitors, stem cell therapy, integrin antagonists, tumor necrosis inhibitors and immunomodulators.
- Analysis of current and future competition in the global CD therapeutics market. Key market companies covered are: GlaxoSmithKline plc, Johnson & Johnson, Osiris Therapeutics, Inc., and Takeda Pharmaceutical Company Limited..
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the CD therapeutics market.
- Analysis of key recent licensing and partnership agreements in the CD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and through identification of companies with the strongest pipelines.
- Develop business strategies through understanding of the trends which shape and drive the global CD therapeutics market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global CD therapeutics market in the future.
- Formulate effective sales and marketing strategies through understanding of the competitive landscape and analysis of the performance of various competitors.
- Identify emerging companies with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying market categories and segments that present the best opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global CD therapeutics market landscape? Identify, understand and capitalize.
By: GlobalData
 
 
 

Browse Catalogue

 Retail Industry Market Research Reports
 

Related Industries

Healthcare Industry
 

Related Reports

 
 
 US Office
822 East Evelyn Avenue
# 722 , Sunnyvale
CA, USA
Zip: 94087
Tel: +1-408-5308892
info@marketsmonitor.com
 India Office
Plot No. 55, FIE
Patparganj Industrial Area
Delhi, India - 110092
Tel:-+91-11-42141242
       +91-9811336614
info@marketsmonitor.com

Please Fill the Information

Name:
Email: *
Phone:
Company: